Literature DB >> 26280010

A quantitative, surface plasmon resonance-based approach to evaluating DNA binding by the c-Myc oncoprotein and its disruption by small molecule inhibitors.

Huabo Wang1, Anand Ramakrishnan2, Steven Fletcher3, Edward V Prochownik4.   

Abstract

The use of small molecules to interfere with protein-protein interactions has tremendous therapeutic appeal and is an area of intense interest. Numerous techniques exist to assess these interactions and their disruption. Many, however, require large amounts of protein, do not allow interactions to be followed in real time, are technically demanding or require large capital expenditures and high levels of expertise. Surface plasmon resonance (SPR) represents a convenient alternative to these techniques with virtually none of their disadvantages. We have devised an SPR-based method that allows the heterodimeric association between the c-Myc (Myc) oncoprotein and its obligate partner Max to be quantified in a manner that agrees well with values obtained by other methods. We have adapted it to examine the ability of previously validated small molecules to interfere with Myc-Max heterodimerization and DNA binding. These inhibitors comprised two distinct classes of molecules that inhibit DNA binding by preventing Myc-Max interaction or distorting pre-formed heterodimers and rendering them incapable of DNA binding. Our studies also point out several potential artifacts and pitfalls to be considered when attempting to employ similar SPR-based methods. This technique should be readily adaptable to the study of other protein-protein interactions and their disruption by small molecules.

Entities:  

Keywords:  10058-F4; 10074-G5; JKY-2-169; Max; c-Myc; intrinsically disordered proteins

Year:  2015        PMID: 26280010      PMCID: PMC4537179          DOI: 10.14440/jbm.2015.54

Source DB:  PubMed          Journal:  J Biol Methods        ISSN: 2326-9901


  32 in total

1.  Small-molecule perturbation of competing interactions between c-Myc and Max.

Authors:  Ariele Viacava Follis; Dalia I Hammoudeh; Andrew T Daab; Steven J Metallo
Journal:  Bioorg Med Chem Lett       Date:  2008-12-10       Impact factor: 2.823

Review 2.  An overview of recent advances in structural bioinformatics of protein-protein interactions and a guide to their principles.

Authors:  Govindarajan Sudha; Ruth Nussinov; Narayanaswamy Srinivasan
Journal:  Prog Biophys Mol Biol       Date:  2014-07-29       Impact factor: 3.667

Review 3.  Evaluating protein-protein interaction (PPI) networks for diseases pathway, target discovery, and drug-design using 'in silico pharmacology'.

Authors:  Chiranjib Chakraborty; George Priya Doss C; Luonan Chen; Hailong Zhu
Journal:  Curr Protein Pept Sci       Date:  2014       Impact factor: 3.272

4.  Distinct roles for MAX protein isoforms in proliferation and apoptosis.

Authors:  H Zhang; S Fan; E V Prochownik
Journal:  J Biol Chem       Date:  1997-07-11       Impact factor: 5.157

5.  Recognition by Max of its cognate DNA through a dimeric b/HLH/Z domain.

Authors:  A R Ferré-D'Amaré; G C Prendergast; E B Ziff; S K Burley
Journal:  Nature       Date:  1993-05-06       Impact factor: 49.962

Review 6.  MYC oncogenes and human neoplastic disease.

Authors:  C E Nesbit; J M Tersak; E V Prochownik
Journal:  Oncogene       Date:  1999-05-13       Impact factor: 9.867

7.  Multiple independent binding sites for small-molecule inhibitors on the oncoprotein c-Myc.

Authors:  Dalia I Hammoudeh; Ariele Viacava Follis; Edward V Prochownik; Steven J Metallo
Journal:  J Am Chem Soc       Date:  2009-06-03       Impact factor: 15.419

8.  Pharmacophore identification of c-Myc inhibitor 10074-G5.

Authors:  Jeremy L Yap; Huabo Wang; Angela Hu; Jay Chauhan; Kwan-Young Jung; Robert B Gharavi; Edward V Prochownik; Steven Fletcher
Journal:  Bioorg Med Chem Lett       Date:  2012-10-17       Impact factor: 2.823

9.  Disruption of Myc-Max heterodimerization with improved cell-penetrating analogs of the small molecule 10074-G5.

Authors:  Huabo Wang; Jay Chauhan; Angela Hu; Kelsey Pendleton; Jeremy L Yap; Philip E Sabato; Jace W Jones; Mariarita Perri; Jianshi Yu; Erika Cione; Maureen A Kane; Steven Fletcher; Edward V Prochownik
Journal:  Oncotarget       Date:  2013-06

10.  Targeting of the MYCN protein with small molecule c-MYC inhibitors.

Authors:  Inga Müller; Karin Larsson; Anna Frenzel; Ganna Oliynyk; Hanna Zirath; Edward V Prochownik; Nicholas J Westwood; Marie Arsenian Henriksson
Journal:  PLoS One       Date:  2014-05-23       Impact factor: 3.240

View more
  8 in total

Review 1.  MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies.

Authors:  Seyed Esmaeil Ahmadi; Samira Rahimi; Bahman Zarandi; Rouzbeh Chegeni; Majid Safa
Journal:  J Hematol Oncol       Date:  2021-08-09       Impact factor: 17.388

2.  Direct inhibition of c-Myc-Max heterodimers by celastrol and celastrol-inspired triterpenoids.

Authors:  Huabo Wang; Peter Teriete; Angela Hu; Dhanya Raveendra-Panickar; Kelsey Pendelton; John S Lazo; Julie Eiseman; Toril Holien; Kristine Misund; Ganna Oliynyk; Marie Arsenian-Henriksson; Nicholas D P Cosford; Anders Sundan; Edward V Prochownik
Journal:  Oncotarget       Date:  2015-10-20

Review 3.  Kinetics and kinematics of diabetic foot in type 2 diabetes mellitus with and without peripheral neuropathy: a systematic review and meta-analysis.

Authors:  Animesh Hazari; Arun G Maiya; K N Shivashankara; Ioannis Agouris; Ashma Monteiro; Radhika Jadhav; Sampath Kumar; C G Shashi Kumar; Shreemathi S Mayya
Journal:  Springerplus       Date:  2016-10-19

4.  OsMADS57 together with OsTB1 coordinates transcription of its target OsWRKY94 and D14 to switch its organogenesis to defense for cold adaptation in rice.

Authors:  Liping Chen; Yuan Zhao; Shujuan Xu; Zeyong Zhang; Yunyuan Xu; Jingyu Zhang; Kang Chong
Journal:  New Phytol       Date:  2018-01-24       Impact factor: 10.151

Review 5.  Strategies to Inhibit Myc and Their Clinical Applicability.

Authors:  Jonathan R Whitfield; Marie-Eve Beaulieu; Laura Soucek
Journal:  Front Cell Dev Biol       Date:  2017-02-23

6.  Inhibition of hepatocellular carcinoma by metabolic normalization.

Authors:  Huabo Wang; Jie Lu; James Dolezal; Sucheta Kulkarni; Weiqi Zhang; Angel Chen; Joanna Gorka; Jordan A Mandel; Edward V Prochownik
Journal:  PLoS One       Date:  2019-06-26       Impact factor: 3.240

Review 7.  Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc.

Authors:  Sarah K Madden; Aline Dantas de Araujo; Mara Gerhardt; David P Fairlie; Jody M Mason
Journal:  Mol Cancer       Date:  2021-01-04       Impact factor: 27.401

Review 8.  Diabetic Neuropathy and Gait: A Review.

Authors:  Uazman Alam; David R Riley; Ravinder S Jugdey; Shazli Azmi; Satyan Rajbhandari; Kristiaan D'Août; Rayaz A Malik
Journal:  Diabetes Ther       Date:  2017-09-01       Impact factor: 2.945

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.